New surface live. Education & Therapy Robotics residual execution: Robot / avatar event → portal log → teacher + caregiver drafts → evidence packet → human gate → audit dossier. Same client-side runtime. Same human approval boundary. Synthetic only. Walk the full loop: sensorlens.app/robotics.html If your teams still carry the last-mile work after a lesson, check-in, or support event — I want to hear which workflow is actually painful. hans@lensdna.app

@grok @boardyai Most systems still leave residual non-API work on people. LensDNA is built specifically to execute that residual under existing systems, with a human gate and audit-ready evidence.

@grok @boardyai What this is not: • Not a learning platform • Not an avatar product • Not robot control software • Not a claim of any existing partnership It is the residual layer: the browser, phone, documentation, and coordination work that remains after the robot creates the event.

Healthcare AI in 2026 has a dirty secret: The decision layer decides what should happen in 300ms. Then a human operator spends 25 minutes copying data across broken, non-API payer portals, fighting phone IVRs, and drafting appeals. The decision isn't the bottleneck. The residual execution is. 🧵👇

@grok @boardyai We built a live reference workstation proving the entire prior-auth loop: Intake ➔ Policy surface ➔ Medical necessity narrative ➔ Telephony notes ➔ Step-therapy appeal ➔ Master PDF dossier. Test the synthetic Wegovy / BCBS flow directly: 🔗 lensdna.app/healthadmindna 📦 Public core: github.com/kaascanvas/LensDN…

Certainty sits in the instrument and the logic — not in a pre-run dollar guarantee. The instrument is now a 14-day pilot that produces baseline-bound Residual Evidence Artifacts. When residual volume is real and parameters are set correctly, the same logic is consistent. When they are not, the artifacts will show it. sensorlens.app/ github.com/kaascanvas/sensor…

The platform decides. The residual is still manual. US prior-auth admin burden is on the order of ~$35B/yr. Intelligence layers improve the decision. Operators still burn minutes on portals, attaches, status, appeals. LensDNA = last-mile residual execution after the decision. Human gate. Client install: Public: github.com/kaascanvas/sensor… Live: sensorlens.app ( + overlay) Sample: lensdna.app/healthadmindna TAM we care about = residual minutes after decisioning — not “all healthcare AI.” Code open. Host live. Measure when residual is thick. Note: ~$35B is system PA admin cost (widely cited), not “LensDNA revenue TAM.” Your real TAM is the residual slice of that work. The posts say that on purpose so SAFE and operators can’t call the number dishonest.

We proved residual last-mile in domain sample at lensdna.app/healthadmindna and in live client-install form at sensorlens.app (same + overlay path clients use). We accept the execution lane and its limits (human gate; residual after decision; client parameters can fail). We are instrumented for the addressable residual TAM under pilot parameters — not under promised by-product economics. Commercial pilot intake: lensdna.app/enterprise.

# Decision question Whether independent home health and outpatient post-acute care operators should deploy human-gated residual execution (HealthAdminDNA) to absorb payer portal navigation, complex prior authorization (PA) bottlenecks, and denial recovery under existing provider systems. # Dated conclusion *March 2026.* Public evidence confirms that manual prior authorization and utilization management (UM) requirements create severe administrative drag for home health and independent clinical operators, directly impacting cash flow, staffing capacity, and patient access. Because non-API payer portal friction resists pure software automation, human-gated last-mile execution offers a viable operational bridge to recover leaked revenue, provided operators isolate a frozen eligible cohort for a 14-day test. # Residual gap (clinical / compliance / staffing / reimbursement) - **Administrative Burden:** Home health agencies and clinical staff spend excessive hours navigating disparate payer portals, tracking attachment requirements, and managing manual prior authorizations. - **Access and Delays:** Upwards of 58% of patients requiring prior authorization experience treatment delays or denials, leading to delayed cash conversion and compromised patient experiences. - **Reimbursement Leakage:** Denials driven by documentation gaps, medical necessity disputes, and complex remittance codes require tedious manual intervention that overwhelms in-house billers and coordinators. # Segment fit (independent operator type) Independent home health agencies, post-acute care providers, medical billing companies, and revenue cycle management (RCM) firms supporting outpatient operators. # Cash-flow / financeable posture Not visible in session. (Public evidence confirms acute operational friction and staffing strain, but specific balance sheet cash flow, profit margins, or deal readiness for named operators are not exposed in public records.) # Economic value proposition (plan bands only) *Note: The following are plan bands underwriting the model, not audited results or guarantees for a named prospect.* - **Defensive floor (plan):** $50,000–$200,000 / year for mid-size operators capturing material denial recovery and accelerated cash flow from residual portal/PA minutes. - **Efficiency upside (plan):** Toward $100,000–$400,000 / year via clean, instant submissions, higher weekly authorization throughput, and reallocation of staff time to high-value revenue work. - **What is certain:** Residual non-API work is real. A 14-day one-workflow pilot on a frozen eligible cohort (with exceptions pre-registered) makes this economic claim testable via measured proxies (processing minutes, clear rate, denial/attachment recovery). - **Logic when implemented correctly:** Upside is consistent and scales as additional residual tasks are added—work that was previously unmanageable without HealthAdminDNA OS. - **Risk split:** LensDNA does not fail the residual execution job under the product rules; the client can fail the set parameters (wrong cohort, thin residual, unfrozen exceptions, non-measurable workflow). Outcomes can go either way until measured. - **Pilot price:** $25,000. A ≤Q1 payback on the defensive floor is a target path if operational proxies support it—not a pre-pilot guarantee. # HealthAdminDNA angle (execution, human gate, pilot shape) - **Execution:** Human-gated last-mile execution operating directly inside existing payer portals, phone queues, and provider systems without requiring costly custom API builds. - **Human Gate:** Trained operators oversee exceptions, clinical documentation matching, and portal submissions to ensure compliance and accuracy. - **Pilot Shape:** A 14-day single-workflow pilot focused on a frozen cohort of prior authorization or denial-recovery bottlenecks to establish baseline proxies. # What to discount - Claims that workflow automation alone (without human-in-the-loop intervention) can resolve non-API payer portal friction. - Unverified vendor assertions of instant 100% first-pass approval rates. - General healthcare staffing solutions that add headcount rather than solving underlying administrative throughput via technology-enabled execution desks. # Confidence Moderate-High (for operational friction and demand for relief); Moderate (for immediate financial quantification prior to pilot validation). # Next monitor / next commercial step - **Next Monitor:** Track regional regulatory changes regarding prior authorization turnaround times and emerging payer portal restrictions. - **Next Commercial Step:** Propose a 14-day, $25,000 single-workflow pilot targeting prior authorization backlogs for an independent home health or RCM operator using a frozen cohort. # Expansion path (next residual tasks / seats / mandate) - **Expansion Ladder:** Begin with prior authorization processing → expand to complex denial appeals and medical records attachments → scale seats and operational lanes → establish a recurring residual execution mandate. - **Portfolio Crosslink:** When multiple independent agencies or clinics operate under a shared umbrella (e.g., private equity healthcare portfolios or regional MSOs), proven residual workflow patterns can be systematically transferred across entities as optional portfolio-wide upside. (Never claim affiliation unless explicit evidence exists). # One-line pilot ask Deploy HealthAdminDNA for a 14-day, $25,000 single-workflow pilot on a frozen prior authorization cohort under your existing systems to test our human-gated residual execution model against your current leakage and staff minutes. lensdna.app/healthcare